Stock Ratings | UBS raised its price target for Micron Technology (MU) to $1,625; Needham lowered its price target for Cartesian Therapeutics (RNAC) to $40, indicating a potential upside of 520.16%.
Dakota Gold Corp DC | 0.00 | |
Tectonic Therapeutic Inc TECX | 0.00 | |
Relay Therapeutics, Inc. RLAY | 0.00 | |
Avalyn Pharma AVLN | 0.00 | |
Cartesian Therapeutics, Inc. RNAC | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Canaccord Genuity: Maintaining Dakota Gold ( Dakota Gold Corp(DC.US) ) rating at "Speculative Buy", while raising the price target from $16 to $18.
Raymond James: Upgraded Tectonic Therapeutic ( Tectonic(TECX.US) ) stock rating to "Strong Buy", raising the price target from $76 to $81.
HC Wainwright & Co.: Maintaining a "buy" rating on Relay Therapeutics ( Relay Therapeutics(RLAY.US) ), with a price target raised from $25 to $28.
Guggenheim: Initial rating for Avalyn Pharma ( Avalyn Pharma(AVLN.US) ) stock at "buy", with a target price of $80.
Needham: Maintain Cartesian Therapeutics' rating ( Cartesian Therapeutics(RNAC.US) ) at "Buy", while lowering the target price from $42 to $40.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Dakota Gold Corp(DC.US) | to lift | $18.0 | $5.66 | 218.02% | Canaccord Genuity |
| Tectonic(TECX.US) | to lift | $81.0 | $29.99 | 170.09% | Raymond James |
| Relay Therapeutics(RLAY.US) | to lift | $28.0 | $14.17 | 97.6% | HC Wainwright & Co. |
| Relay Therapeutics(RLAY.US) | to lift | $26.0 | $14.17 | 83.49% | Guggenheim |
| Immunovant(IMVT.US) | to lift | $62.0 | $33.83 | 83.27% | Guggenheim |
| Avalyn Pharma(AVLN.US) | Initial classification | $80.0 | $26.7 | 199.63% | Guggenheim |
| Cartesian Therapeutics(RNAC.US) | cut | $40.0 | $6.45 | 520.16% | Needham |
| Chewy(CHWY.US) | cut | $43.0 | $21.25 | 102.35% | Morgan Stanley |
| Celsius Holdings(CELH.US) | cut | $57.0 | $29.67 | 92.11% | BNP Paribas |
| Chewy(CHWY.US) | cut | $40.0 | $21.25 | 88.24% | Barclays |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
B of A Securities: Maintaining Apple's rating Apple Inc.(AAPL.US) ) at "Buy", while raising the target price from $330 to $380.
BTIG: Maintaining a "Buy" rating on CrowdStrike Holdings CrowdStrike(CRWD.US) , raising the price target from $621 to $764
BTIG: Maintain Datadog's ( Datadog(DDOG.US) ) rating at "Buy", while raising the target price from $212 to $255.
HSBC: Upgrades Marvell Technology Marvell Technology(MRVL.US) ) stock to "buy", raising its price target from $85 to $300.
UBS: Maintaining a "buy" rating on Micron Technology Micron Technology(MU.US) , while raising its price target from $535 to $1625.
Barclays: Upgraded Occidental Occidental Petroleum(OXY.US) ) stock to "overweight", raising its price target from $59 to $72.
BTIG: Maintaining a "buy" rating on Palo Alto Networks Palo Alto Networks, Inc.(PANW.US) ) stock, while raising the price target from $216 to $268.
Evercore ISI Group: Maintaining Western Digital's ( Western Digital(WDC.US) ) rating at "Outperform Market", while raising the price target from $500 to $575.
First Coverage
Morgan Stanley: Initial rating for Avalyn Pharma ( Avalyn Pharma(AVLN.US) ) at "overweight", with a target price of $53.
Wells Fargo: Initial rating for Pershing Square ( Pershing Square(PS.US) ) at "Market-like weight", with a price target of $37.
Stifel: Initial rating for Seaport Therapeutics ( Seaport Therapeutics(SPTX.US) ) at "Buy", with a target price of $30.
Susquehanna: Initial rating on Woodward Woodward(WWD.US) ) stock at "positive", with a price target of $423.
reduction
B of A Securities: Maintaining a "neutral" rating on Hims & Hers Health ( Hims & Hers Health(HIMS.US) ), while lowering the price target from $28 to $25.
Citigroup: Maintaining a "buy" rating on Matador Resources ( Matador Resources(MTDR.US) ), while lowering the price target from $77 to $72.
Cantor Fitzgerald: Maintaining Snowflake's ( Snowflake(SNOW.US) rating at "overweight," while lowering the price target from $250 to $225.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.